Cologne

• Phase 2b Randomized, Double-Blind Study with Phage for CF Subjects with Pseudomonas Lung Infection Ended
  2024-519856-94-00 4 2025-08-18 Cystic fibrosis
• Phase 2 Open Label Prospective Dose-Ranging Clinical Trial with Escalation and Expansion Cohorts to Evaluate Safety, Tolerability, Pharmacok … Ended
  2024-510582-42-02 4 2025-08-14 Acute graft versus host disease (aGvHD)
• Study to test new drug eftilagimod alfa (also known as efti) combined with standard marketed treatments (pembrolizumab and chemotherapy) in … Ended
  2024-513621-23-00 5 2025-04-18 Advanced/metastatic non-small cell lung cancer (NSCLC)
• Integrated PK/efficacy, safety, and immunogenicity study to demonstrate similarity of JPB898, a proposed biosimilar to nivolumab, to Opdivo® … Ended
  2023-507865-24-00 5 2025-03-28 Advanced (unresectable/metastatic) melanoma
• A Phase 1 Study of PRT7732, an Oral SMARCA2 Degrader, in Patients with Advanced or Metastatic Solid Tumors with a SMARCA4 Mutation Ended
  2024-512380-32-00 1 2025-03-03 esophageal, gastric, or gastroesophageal junction adenocarcinoma
• Randomized, Double-Blind, Placebo and Active Comparator Controlled Phase 3 Study of Efficacy and Safety of ESK-001 for Moderate to Severe Pl … Ended
  2023-507193-40-00 5 2025-01-16 Moderate to Severe Plaque Psoriasis
• A study to learn how well bimekizumab works and how safe it is in adults with psoriatic arthritis Ended
  2024-511738-11-00 5 2024-12-18 Psoriatic arthritis
• A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Vosoritide in Children Wit … Ended
  2024-513129-22-00 5 2024-12-17 Hypochondroplasia
• A prospective, randomized, double-blind placebo-controlled multicentre trial with mannan-conjugated birch pollen allergoids administered sub … Ended
  2024-515717-17-00 5 2024-10-28 birch pollen-induced allergic rhinitis birch pollen-induced allergic r
• Prospective pilot trial to address the feasibility and safety of treatment with oral Zinc in GNAO1 associated disorders (ZINCGNAO1) Ended
  2024-512735-72-00 4 2024-07-30 GNAO1 associated disorders
• A randomized, double-blind, dose-ranging, placebo-controlled study to evaluate the efficacy and safety of PLN-74809 (bexotegrast) for the tr … Ended
  2023-506185-31-00 10 2024-07-18 Idiopathic pulmonary fibrosis (IPF)
• Randomized adaptive assessment of post COVID syndrome treatments (RAPID) Reducing Inflammatory Activity in Patients with post COVID Syndrome … Ended
  2024-511628-16-00 4 2024-07-18 Post Covid Syndrome (PCS)
• Effects of maintenance cabozantinib+BSC versus BSC in children and AYA with osteosarcoma. ( CabOSTar ) Ended
  2023-506229-12-00 4 2024-06-26 Osteosarcoma in Children
• A randomized, multicenter, open-label trial comparing the effectiveness of Inclisiran to bempedoic acid on LDL cholesterol (LDL-C) lowering … Ended
  2024-511076-32-00 6 2024-06-21 Hypercholesterolemia
• A Study designed to evaluate the efficacy and safety of tiragolumab plus atezolizumab compared with placebo plus atezolizumab administered i … Ended
  2023-506696-10-00 5 2024-06-18 Non-Small Cell Lung Cancer
• A Safety, Efficacy and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined with Atezolizumab in Non-Hodgkin's … Ended
  2023-506820-10-00 9 2024-06-11 B-Cell Malignancies
• A Two-Part Study to Assess the Effectiveness, Safety, and Blood Levels of Repeat Doses of Inhaled ETD001 in People with Cystic Fibrosis Ended
  2023-504092-25-00 4 2024-06-04 Cystic Fibrosis
• A Phase 1/2 Study of TAS3351 in Patients with Advanced Non-Small Cell Lung Cancer and EGFR Mutations Ended
  2022-502595-23-00 7 2024-05-21 Patients with locally advanced or metastatic non-small cell lung cance
• A Phase 1/2a Dose-Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARO-C3 in Adult Healthy V … Ended
  2023-506690-36-00 9 2024-05-06 complement-mediated renal disease
• A Study to Evaluate the Efficacy and Safety of Faricimab in Patients with Choroidal Neovascularization Secondary to Pathologic Myopia Ended
  2023-506707-25-00 5 2024-04-09 Choroidal neovascularization secondary to pathologic myopia
• A Study to Investigate the Safety and Efficacy of KER-012 in Combination With Background Therapy in Adult Participants With Pulmonary Arteri … Ended
  2022-502378-17-00 4 2024-03-20 Pulmonary Arterial Hypertension
• A proof of concept and dose-finding study of XXB750 in patients with heart failure Ended
  2023-504678-39-00 4 2024-03-13 Heart Failure
• Study Drug vs Placebo as an “add on” treatment for Severe Community-Acquired Pneumonia. Ended
  2023-505985-28-01 4 2024-03-04 Severe Community-Acquired Pneumonia
• Proof of concept treatment study of orally administered VH4004280 or VH4011499 in HIV-1 infected adults Ended
  2023-505350-18-00 4 2023-12-15 HIV Infections

Showing 457–480 of 577 trials